文献速递肝病消化道肿瘤与早癌

肝细胞癌基因组与转录组分析识别转化生长因子-β通路中的突变与基因表达改变

Analysis of Genomes and Transcriptomes of Hepatocellular Carcinomas Identifies Mutations and Gene Expression Changes in the Transforming Growth Factor-β Pathway.
PubMed 文献 · Gastroenterology · 2017-09-15

该研究整合分析488例肝细胞癌的转录组及基因组数据,发现38%的样本中至少一个转化生长因子-β(TGF-β)信号通路基因存在体细胞突变,SPTBN1突变比例最高(12/202,6%)。转录组无监督聚类识别出TGF-β通路激活与失活两组,失活组患者生存期较短(P = .0129)。表达D1089Y突变体或敲低SPTBN1的细胞对DNA交联剂敏感性增加且存活率降低。

要点

  • 38%的肝细胞癌样本中至少一个TGF-β信号通路基因存在体细胞突变,SPTBN1突变占12/202(6%)。
  • 转录组聚类识别出TGF-β通路激活与失活两组,失活组患者生存期较激活组短(P = .0129)。
  • 表达SPTBN1 D1089Y突变体或敲低SPTBN1的HepG2、SNU398、SNU475细胞对DNA交联剂敏感性增加且存活率降低。

核心结论

  • 在肝细胞癌基因组与转录组分析中,发现近40%样本存在TGF-β信号通路基因突变,这些突变与通路基因表达改变相关;通路上调可能促进炎症和纤维化,下调则提示TGF-β抑癌活性丧失。
  • 作者认为,基于TGF-β通路的遗传特征,肝细胞癌治疗药物可能有效;阻断TGF-β的药物应仅用于特定类型的肝细胞癌患者。

研究设计与样本

  • 研究对总共488例肝细胞癌进行转录组分析,包括来自癌症基因组图谱(The Cancer Genome Atlas)的数据。
  • 研究在癌症体细胞突变目录(Catalogue of Somatic Mutations in Cancer)报告的301例肝细胞癌和癌症基因组图谱的202例肝细胞癌中筛查了基因组序列突变。
  • 研究在HepG2、SNU398和SNU475细胞中表达突变型非红细胞血影蛋白β1(SPTBN1),并检测SMAD家族成员3(SMAD3)的磷酸化、核转位和转录活性。

主要发现

  • 在38%的肝细胞癌样本中,至少一个产物为TGF-β信号通路成员的基因存在体细胞突变;SPTBN1在最大比例样本中突变(12/202,6%)。
  • 转录组数据无监督聚类识别出一组TGF-β信号通路激活(通路基因转录增加)的肝细胞癌和一组TGF-β信号失活(通路基因表达降低)的肝细胞癌。
  • TGF-β信号失活肿瘤患者生存时间短于TGF-β信号激活肿瘤患者(P = .0129)。
  • TGF-β信号模式与DNA损伤应答及sirtuin信号通路的激活相关。
  • 表达D1089Y突变体或敲低SPTBN1的HepG2、SNU398和SNU475细胞,与表达正常SPTBN1的对照细胞相比,对DNA交联剂敏感性增加且存活率降低。

临床怎么用

  • 作者认为,基于TGF-β通路的遗传特征,肝细胞癌治疗药物可能有效。
  • 作者认为,阻断TGF-β的药物应仅用于特定类型的肝细胞癌患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Development of hepatocellular carcinoma (HCC) is associated with alterations in the transforming growth factor-beta (TGF-β) signaling pathway, which regulates liver inflammation and can have tumor suppressor or promoter activities. Little is known about the roles of specific members of this pathway at specific of HCC development. We took an integrated approach to identify and validate the effects of changes in this pathway in HCC and identify therapeutic targets. METHODS: We performed transcriptome analyses for a total of 488 HCCs that include data from The Cancer Genome Atlas. We also screened 301 HCCs reported in the Catalogue of Somatic Mutations in Cancer and 202 from Cancer Genome Atlas for mutations in genome sequences. We expressed mutant forms of spectrin beta, non-erythrocytic 1 (SPTBN1) in HepG2, SNU398, and SNU475 cells and measured phosphorylation, nuclear translocation, and transcriptional activity of SMAD family member 3 (SMAD3). RESULTS: We found somatic mutations in at least 1 gene whose product is a member of TGF-β signaling pathway in 38% of HCC samples. SPTBN1 was mutated in the largest proportion of samples (12 of 202, 6%). Unsupervised clustering of transcriptome data identified a group of HCCs with activation of the TGF-β signaling pathway (increased transcription of genes in the pathway) and a group of HCCs with inactivation of TGF-β signaling (reduced expression of genes in this pathway). Patients with tumors with inactivation of TGF-β signaling had shorter survival times than patients with tumors with activation of TGF-β signaling (P = .0129). Patterns of TGF-β signaling correlated with activation of the DNA damage response and sirtuin signaling pathways. HepG2, SNU398, and SNU475 cells that expressed the D1089Y mutant or with knockdown of SPTBN1 had increased sensitivity to DNA crosslinking agents and reduced survival compared with cells that expressed normal SPTBN1 (controls). CONCLUSIONS: In genome and transcriptome analyses of HCC samples, we found mutations in genes in the TGF-β signaling pathway in almost 40% of samples. These correlated with changes in expression of genes in the pathways; up-regulation of genes in this pathway would contribute to inflammation and fibrosis, whereas down-regulation would indicate loss of TGF-β tumor suppressor activity. Our findings indicate that therapeutic agents for HCCs can be effective, based on genetic features of the TGF-β pathway; agents that block TGF-β should be used only in patients with specific types of HCCs.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Chen J, Zaidi S, Rao S, et al. Analysis of Genomes and Transcriptomes of Hepatocellular Carcinomas Identifies Mutations and Gene Expression Changes in the Transforming Growth Factor-β Pathway. Gastroenterology. 2017. PMID: 28918914. doi:10.1053/j.gastro.2017.09.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。